Buradasınız

Anasayfa » Content

FIRAT HAVZASINDA SEREBROVASKÜLER HASTALIKLARLA LİPOPROTEİN (A) ARASINDAKİ İLİŞKİ

The Association Between Cerebrovascular Diseases And Lipoprotein (A) In The Fırat River-Basin

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Lipoprotein (a) [Lp (a)] is a cholesterol-rich lipoprotein. High plasma levels of Lp (a) have been shown to be associated with cerebrovascular diseases (CVD). Serum Lp (a) levels are closely related to genetic factors. We determined plasma Lp (a) levels in CVD for population in the Fırat River-Basin, and compared them with previous findings of the other studies. Plasma Lp (a) levels were evaluated in CVD and control groups. The mean plasma Lp (a) levels in the CVD group was found approximately two-fold higher than that of the control group (0.19 g/I vs 0.43 g/I). As a result, high serum Lp (a) levels were found to constitute an independent risk factor in CVD. We believe that patients who have a high Lp (a) values must be warned for a probable CVD and other risk factors like smoking, alcohol, diet, etc.
Bookmark/Search this post with
Abstract (Original Language): 
Lp (a) kolesterolden zengin bir lipoproteindir. Yüksek Lp (a) seviyelerinin serebro vasküler hastalıklarla (SVH) ilişkisi gösterilmiştin Serum Lp (a) düzeyleri oldukça sıkı bir genetik kontrol altındadır. Yapılan çalışmalarda serum Lp (a) konsantrasyonlarının, popülasyonlar arasında hatta aynı popülasyonun bireyleri arasında oldukça farklı değerler gösterdiği tespit edilmiştir. Biz bu çalışmada, Fırat havzasındaki SVH'lı ve sağlıklı bireylerde Lp (a) düzeylerini tespit ederek, daha önce yapılan çalışmalarda elde edilen sonuçlar ile karşılaştırdık. SVH gelişimi ile serum Lp (a) düzeyleri arasında ilişki olup olmadığını araştırdık (kontrol grubu 0,19 g/dL; SVH grubunda 0,43 g/dL). Serum Lp (a) düzeylerinin, SVH grubunda tek başına anlamlı bir ateroskleroz risk parametresi oluşturabileceğini belirledik. Yüksek Lp (a) değerlerine sahip bireylerin belirlenerek diğer risk faktörleri açısından (sigara, alkol, diyet vs.) uyarılmaları gerektiğine inanıyoruz.
FULL TEXT (PDF): 
PDF icon arastirmax-firat-havzasinda-serebrovaskuler-hastaliklarla-lipoprotein-arasindaki-iliski.pdf
  • 3
197-202
  • Turkish

REFERENCES

References: 

1. Simon RP, Aminoff MJ, Greenberg DA. Clinical Neurology. USA: Appleton & Lange, 1989: 220-41.
2. Adams RD, Victor M, Roper AH. Principles of Neurology.6th ed., New York: McGraw-Hill, 1997:777-835.
3. Rowland LP. Merntfs Textbook of Neuroloy.901 ed., Baltimore: Williams & Wilkins, 1995:227-39.
4.
Kumra
l K, Kumral E. Santral Sinir Sisteminin Damarsal Hastalıkları. İzmir: Ege Üniversitesi Tıp Fakültesi Yayınları, 1993: 25-46.
5.
Erteki
n C. Noroloji'de fizyopatoloji ve tedavi. İzmir: Bilgehan yayınları,1987:627-8.
6.
Gökdemi
r 0,Palaoğlu KE. Aterogenezin Hücresel ve Moleküler Biolojisi. İstanbul: Merck & Co. Inc., 1993: 45-151.
7. Utermann G. The mysteries of lipoprotein (a). Science 1983;249:904-10
8. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kantz JA, Gotto AM Jr. Association of levels of lipoprotein Lp (a), Plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-65.
9. Harrie NR, Schultz JS. Studies of Lp-lipoprotein as a quantitative genetic tract. Proc Natl Acad Sci USA 1970; 66: 99-103.
10. Sandholzer C, Hallmar DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E and Uterman G. Effects of the apolipoprotein (a) size polymorphism on the lipoprotein (a) concentration in 7 ethnic groups. Hum Genet 1991; 86: 607-14.
11. Örem A, Değer O, Önder E. Distribution of serum lipoprotein (a) concentrations in a healthy Turkish population. Ann Clin Biochem 1994;31:343-6.
12. İlhan A , Alioğlu Z , Adanır M, Özmenoğlu M, Örem A. Association of levels of lipoprotein(a) and other lipoproteins with cerebrovascular disease in the Turkish population. European Journal of Neurology 1996; 3: 1-4.
13.
Duma
n T, Melek İ, Eraslan T, Özbakır Ş. Tekrarlayan stroklarda lipoprotein (a). Türk Nöroloji Dergisi,abstracts 1997; 3: 57-8.
14. Maximilian K. A new "capture" immunoassay for human Lp(a) lipoprotein (EUSA). DAI 1989 ; 51: 152-5.
15. Rössner S. Serum lipoproteins and ischemic vascular disease: On the interpretation of serum lipid versus serum lipoprotein concentrations.J Cardiovasc Pharmacol 1982; 4: 201-5.
16. Hassted SJ, Wilson DE, Edwards CQ, Connon WN, Carmelli D and Williams RR. The genetics of quantitative vs. plasma Lp (a): analysis of a large pedigree. Ann J Med Genet 1983; 16: 179-88.
17. Kostner GM. Apolipoproteins and lipoproteins of human plasma. Significance in health and in disease. Adv Lipid Res. 1983; 20: 1-7.
18. Ağaoglu L. Kara G. Emir C. Samurkas P. Tanık O. Akut serebral infarklı hastalarda serum lipoprotein düzeyleri.Türk Nöroloji Dergisi, abstracts 1998; 4: 53.
19. Scanu AM, Lawn RM and Berg K. Lipoprotein (a) and atherosclerosis. Ann Int Med. 1991; 15: 209-18.
20. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolobon G, Quinci GB. Lippoprotein Lp (a) and the risk for myocardial infarction. Atherosclerosis 1987; 38:51-61.
21. Rhoads GG, Dahlen G, Berg K, Morton NE and Dannenberg AL. Lp (a) Lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256: 2540.
22. Guyton JR, Dahlen GH, Patsch W, Kautz JA and Gotto AM Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985; 5: 265-72.
23. Zenker G, Költringer P, Bone G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17: 942-5.
24. Nagayama M, Shinohara Y and Nagayama T. Lipoprotein (a) and ischemic cerebrovascular disease in young adults. Stroke 1994;25:74-8.
25. Pedro-Botet J, Senti M, Nogues X, Rubies-Prat J, Roguer and Olhaberriague L. Lipoprotein and apolipoprotein profile in men with ischemic stroke. Stroke 1992; 23: 1556-62.
26. Költringer P and Jürgens GA. A dominant role of lipoprotein (a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985; 58: 643-8.
27. Jürgens G and Költringer P. Lipoprotein (a) in ischemic cerebrovascular disease: A new approach to the assessment of risk for stroke. Neurology 37: 513-515, 1987.
28. Murai A, Miyahara T,Fujimoto N, Matsuda M, Kameyema M. Lp (a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204.
29. Loscalzo C. Lipoprotein (a): A unique risk factor for atherotrombotic disease. Arteriosclerosis 1990; 10: 672-8.

Thank you for copying data from http://www.arastirmax.com